Study guide
4.3 Drug & Dosage-Form Factors
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
4.3 Drug & Dosage-Form Factors
Key Takeaways Explain This Topic AI
Pharmacokinetic interactions, food effects, and formulation (IR vs MR) change exposure, timing, and counselling points.
Swallowing difficulties and device technique are dosage-form problems that can look like therapeutic failure.
Bioavailability traps include crushing MR products, food-dependent absorption, and switching between non-equivalent forms.
Renal clearance and narrow therapeutic index drugs demand extra vigilance on dose, interactions, and brand consistency where required.
Australian brand/generic practice uses bioequivalence principles, but some medicines need care with brands, devices, or critical-dose drugs.
Last updated: August 2026
4.3 Drug & Dosage-Form Factors
Quick Answer: The “right drug” can still fail or harm if the formulation, food timing, device, crushing practice, renal clearance, or brand/generic switch is wrong. Assess pharmacokinetic traps, IR vs MR behaviour, swallowing and device barriers, narrow therapeutic index risks, and Australian equivalence concepts before finalising a plan.
Standard 3.1 explicitly includes drug and dosage-form factors alongside patient factors. Intern Written items often turn on a formulation detail rather than the drug class headline.
Pharmacokinetic (PK) interactions that change management
PK interactions alter absorption, distribution, metabolism, or excretion — changing concentration without necessarily sharing the same receptor.
High-yield patterns:
Mechanism Classic examples (illustrative) Clinical response
CYP inhibition Strong inhibitors raising levels of substrates Avoid combination, reduce dose, or intensify monitoring
CYP induction Inducers lowering efficacy of substrates Avoid, increase dose only under specialist plans, or choose alternative
P-gp / transporter effects Absorption/distribution changes for some substrates Check AMH interaction monographs
Chelation / binding in gut Tetracyclines/quinolones with calcium, iron, antacids; levothyroxine with binders Separate dosing times; counsel clearly
pH-dependent absorption Some antifungals/antivirals with acid suppression Avoid PPI/H2 combinations when absorption critical
Renal excretion competition / reduced GFR Accumulation of renally cleared drugs Dose adjust or avoid
Exam habit: When two medicines are both “reasonable alone,” ask whether concentration of one will rise or fall. Bleeding risk with anticoagulants can be PD (additive effect) or PK (level increase) — both matter, and counselling differs.
Always verify interaction severity and management in AMH under open-book conditions rather than relying on memory of every CYP pair.
Food effects
Food can increase, decrease, or delay absorption, or reduce GI irritation.
Pattern Implication
Take with food Improve tolerability (e.g. many NSAIDs, metformin GI tolerance) or required absorption for some agents
Take on empty stomach Food reduces absorption (e.g. some bisphosphonates — also upright posture and full glass of water)
Consistent with respect to meals Critical for drugs where variability changes control (e.g. some diabetes regimens, certain modified-release products)
Alcohol / grapefruit-type interactions Not “food” in the casual sense but dietary exposures that alter PK/PD
Counselling must be specific : “with breakfast” is better than “with food” if timing relative to other medicines matters. For bisphosphonates, incomplete counselling creates oesophagitis risk and treatment failure.
Formulation switches: IR vs MR (and related)
Immediate-release (IR) and modified-release (MR/SR/CR/XL — terminology varies by product) are not interchangeable on a milligram-for-milligram assumption without checking the product.
Key principles:
MR products often cannot be crushed, chewed, or split unless the particular product allows it (some scored MR forms exist — verify).
Switching IR ↔ MR usually requires prescriber-directed conversion , not pharmacy improvisation.
MR aims for fewer daily doses or steadier levels; inappropriate IR substitution can cause peak toxicity or trough failure.
“Burst” dumping from crushed MR opioids or other MR CNS drugs can be fatal — a critical safety teaching point.
Related formulation pitfalls:
- Enteric-coated products crushed → loss of protection, gastric irritation, or inactivation
- Sublingual / orodispersible products swallowed whole → altered onset
- Transdermal patches cut or heated → dose dumping or burns risk
- Different salt forms or combination products with similar names → wrong strength selection
- Swallowing difficulties (dysphagia)
Dysphagia is common post-stroke, in Parkinson disease, head-and-neck disease, and frailty. Forcing large tablets risks aspiration and non-adherence.
Assessment:
- Solid oral dose problems vs liquids vs crushable forms
- Whether crushing is pharmaceutically appropriate
- Whether a licensed liquid, dispersible, patch, or alternative route exists
- Thickened fluids and interaction with medicine administration in aged care
Do not crush list mindset: If unsure, check product guidance and professional references before advising crushing. Recommend prescriber review for suitable alternatives when crushing is contraindicated.
Devices: inhalers, injectables, and technique-sensitive forms
Dosage form includes delivery devices .
Inhalers:
- pMDI vs DPI vs soft-mist — different inspiratory flow and coordination needs
- Spacer use for many pMDIs improves lung deposition and reduces oropharyngeal steroid exposure
- Device switches (even same molecule) require re-training
- “Empty” assessment: dose counters vs float tests (product-specific; avoid unsafe myths)
Injectables (patient-administered):
- Insulin pens: priming, needle length, site rotation, storage, cloudy insulin resuspension where relevant
- GLP-1 receptor agonist pens and other weekly injectables: day-of-week routines, missed-dose rules per product
Adrenaline (epinephrine) autoinjectors: carry two when recommended, expiry checks, correct thigh administration, emergency plan after use
Other technique-sensitive forms: eye drops (nasolacrimal occlusion), nasal sprays, topical steroids (fingertip units, site potency), nicotine replacement formats.
Therapeutic failure is often device failure . Recheck technique before escalating dose.
Bioavailability traps
Bioavailability (fraction of dose reaching systemic circulation) is altered by:
- Route and formulation — IV vs oral; MR vs IR; different products of same drug
- First-pass metabolism — oral dose much higher than parenteral for some drugs
- Food and binding interactions — as above
- Crushing / mixing — destroying MR systems or adsorbing drug to enteral tubing
Brand or generic switches for critical-dose drugs — small AUC differences may matter clinically for a minority of agents
Gut integrity / vomiting / diarrhoea — oral absorption unreliable in acute illness
Practical pharmacy examples:
Advising a patient to crush an MR nifedipine-type product (product-dependent) can cause dangerous hypotension from dose dumping — verify before any crush advice
- Levothyroxine absorption reduced by calcium/iron; separate by several hours
- Some oral bisphosphonates require strict fasting and posture rules for both safety and absorption
- Renally cleared drugs
When clearance depends on kidney function, falling eGFR raises exposure and ADR risk.
Approach:
- Identify renally cleared or nephrotoxic agents in the regimen
- Obtain recent renal function when available; if missing and critical, do not guess high-risk doses
- Adjust dose/interval per AMH/product guidance or recommend prescriber adjustment
- Watch “triple whammy” patterns: ACE inhibitor/ARB + diuretic + NSAID → acute kidney injury risk
- Educate on sick-day considerations where clinically appropriate for selected medicines (per local guidance)
Renal dosing is both a drug factor and a patient factor — Standard 3.1 expects you to connect them.
Narrow therapeutic index (NTI) and high-vigilance medicines
NTI drugs have a small gap between effective and toxic concentrations. Management implications:
- Care with dose conversions and formulation changes
- Interaction checks are mandatory
- Therapeutic drug monitoring may be required (e.g. some antiepileptics, lithium, digoxin — context-specific)
- Brand consistency may be preferred for selected agents under clinical guidance
- Patient counselling on toxicity symptoms (e.g. digoxin toxicity features; lithium dehydration risk)
High-risk medicines more broadly (insulin, anticoagulants, opioids, chemotherapy oral agents, concentrated electrolytes in hospitals) deserve heightened double-checks even when not classically labelled NTI.
Australian brand and generic equivalence concepts
Australia’s regulatory framework supports generic substitution based on bioequivalence standards for many PBS medicines, enabling brand substitution policies in community pharmacy within legal and clinical limits.
Exam-level principles:
Bioequivalence means the generic matches the reference for rate and extent of absorption within accepted statistical limits for approved substitutable products — it is not a claim of identical inactive ingredients or appearance.
a-flagging / substitutable brands on the PBS schedule guide which brands may be substituted under PBS rules (know the concept; use current references in practice).
Substitution still requires clinical judgement: patient confusion with different pack appearances, device changes for inhalers, allergy to excipients (rare but real), and critical-dose medicines where prescriber or guidelines prefer brand consistency.
“Generic” is not lower quality by definition in the Australian regulated market; counselling should prevent unnecessary brand anxiety while respecting legitimate clinical exceptions.
Different strengths, salts, or fixed-dose combinations are not automatic substitutes.
Patient-centred counselling on switches:
- Explain same active medicine and expected effect
- Show the pack and name on the label to reduce double-dosing when brands change
- Invite reporting of perceived efficacy/ADR changes — investigate seriously without dismissing
- Integrating drug/form factors into the 3.1 process
When assessing options:
Is the molecule appropriate?
Is the form appropriate for swallow, device skill, and timing?
Do food/PK interactions break the plan?
Does renal/hepatic status change dose?
Is this an NTI/high-risk situation needing extra controls?
Will a brand/device switch confuse or destabilise therapy?
Mini-cases
Case A: Patient with dysphagia is prescribed an MR opioid tablet and family asks to crush it into yoghurt. Correct action is to refuse crushing MR opioid and contact the prescriber for a suitable formulation — crushing risks dose dumping.
Case B: Asthma symptoms worsen after a “same medicine” inhaler brand switch to a different device type. Prioritise technique training and device suitability before assuming disease progression alone.
Case C: Patient takes ciprofloxacin with an iron tablet every morning; infection is not improving. Separate chelating agents from the quinolone by appropriate intervals and reassess.
Drug and dosage-form mastery converts AMH lookup into safe, usable therapy — not just a correct drug name on a label.